Opus Genetics, Inc. (IRD) income statement
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.05+0.01 (+0.25%)
Close on Nov 17, 2026Market cap $336.94MP/E –Yield –
Opus Genetics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -513.5%
- Net margin
- -1091.8%
- Return on equity, FY2025
- -449.4%
Financial strength
- Current ratio
- 12.19
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1167.8%
Valuation
- P/E ratio
- –
- Price to sales
- 34.19
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?